Please login to the form below

Not currently logged in
Email:
Password:

NICE set to reject Pfizer's Ibrance over high cost

Draft guidance on breast cancer therapy calls for more evidence of its benefits
NICE

The National Institute for Health and Care Excellence has ruled that Pfizer's first-in-class breast cancer therapy Ibrance (palbociclib) is not a cost-effective use of NHS resources.

In draft guidance, the UK's watchdog said that while Ibrance has been shown to stall disease progression for an average of 10 months more than the current treatment standard, more clinical evidence is required to quantify overall survival improvement.

Ibrance is a first-line CDK 4/6 inhibitor designed to halt tumour cell growth and delay progression, and is the first oncology therapy that increases the effect of aromatase inhibitors to do so.

It won EU approval in November 2016 for treatment of hormone receptor positive, HER2-negative, locally advanced metastatic breast cancer, and was licensed by the FDA two months ahead of schedule in February 2015.

An estimated 5,500 people in England would be eligible for treatment with Ibrance, however a full course of treatment currently costs £79,650 per patient.

Prof Carole Longson, director of the centre for health technology assessment at NICE, said: “The committee needs more evidence of the drug's impact on overall survival of people with breast cancer. However, even when allowing for these potential benefits, it was still not enough to make palbociclib cost effective at its current price.

“The committee heard from the patient expert that delaying the progression of their cancer for as long as possible and being able to continue with normal activities, including working, is valued very highly by patients and their families.

“It also heard that by postponing disease progression, palbociclib may reduce the number of people who are exposed to the often unpleasant side effects of chemotherapy, and delay the need for such treatment in others.

“Taking the costs into account, the committee concluded that it could not recommend palbociclib for NHS use at present.”

NICE's initial verdict is open to public comment until 24 February, and while it is not minded to back Ibrance now, the guidance does state that patients already receiving the drug should continue to have access to it.

Article by
Rebecca Clifford

2nd February 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics